Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 13/20 | 0.47 |
| ▸ | CPB1 | P15086 | 5/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27304198 | 0.81 | CPB2 (0.46) | CPB2CPB1CPA1 | |
| SCHEMBL17662386 | 0.76 | CPB2 (0.46) | CPB2CPB1CPA1QPCTQPCTL | |
| SCHEMBL17859451 | 0.75 | CPB2 (0.47) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL5912570 | 0.73 | CPB2 (0.54) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL24328256 | 0.72 | CPB2 (0.47) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL24328902 | 0.72 | CPB2 (0.47) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL21686619 | 0.70 | CPA1 (0.51) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL468830 | 0.70 | ITGB2 (0.64) | CPB2QPCTQPCTL | |
| SCHEMBL6026427 | 0.70 | ITGB2 (0.64) | CPB2QPCTQPCTL | |
| SCHEMBL15683044 | 0.70 | ITGB2 (0.64) | CPB2QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018177860-A1 | 2-(4-(4-(BROMO-METHOXYBENZAMIDO)BENZYLAMINO)PHENYL)BENZAZOLE DERIVATIVES AND THEIR USE AS ANTI-HEPARANASE | LEADIANT BIOSCIENCES SA IN LIQUIDAZIONE (CH) | 2018-10-04 | — | — | WO | disclosed |